(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 April 2023 (13.04.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/060253 A1

(51) International Patent Classification:
C07D 519/00 (2006.01) *A61K 47/50* (2017.01)
A61P 35/00 (2006.01) *A61K 31/501* (2006.01)

(21) International Application Number:
PCT/US2022/077784

(22) International Filing Date:
07 October 2022 (07.10.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/254,013 08 October 2021 (08.10.2021) US

(71) Applicant: **REVOLUTION MEDICINES, INC.** [US/US]; 700 Saginaw Drive, Redwood City, CA 94063 (US).

(72) Inventors: **BUCKL, Andreas**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **BURNETT, G., Leslie**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **CREGG, James**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **EDWARDS, Anne, V.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **GILL, Adrian, L.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KNOX, John, E.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **KOLTUN, Elena, S.**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **LIU, Yang**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US). **SEMKO, Christopher**; Revolution Medicines, Inc., 700 Saginaw Drive, Redwood City, CA 94063 (US).

(74) Agent: **BELLIVEAU, Michael, J.**; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2023/060253 A1

(54) Title: RAS INHIBITORS

(57) Abstract: The invention features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.